Organization (Industry)
SOLVAY
ClinicalTrials.gov lists SOLVAY as lead sponsor of 86 trials, counting the companies grouped under it. SOLVAY itself has 29 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Solvay SAS, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers SOLVAY and 4 companies grouped under it: 86 lead-sponsored trials (86 its own, 0 in the grouped companies) and 17 legal-entity registrations (13 its own, 4 in the grouped companies).
Companies grouped under this page (4)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| RHODIA OPERATIONS | 0 | 1 |
| SOLVAY CHIMIE | 0 | 1 |
| SOLVAY OPERATIONS FRANCE | 0 | 1 |
| SOLVAY QUIMICA SL | 0 | 1 |
Disease areas (67)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hypogonadism | 20 |
| Diabetes Mellitus | 15 |
| Schizophrenia | 12 |
| Dyslipidemias | 11 |
| Diabetes Mellitus, Type 2 | 10 |
Showing 5 of 67 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2010 | 2 |
| 2009 | 8 |
| 2008 | 10 |
| 2007 | 21 |
| 2006 | 28 |
| 2005 | 29 |
| 2004 | 19 |
| 2003 | 8 |
| 2002 | 5 |
| 2001 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 86 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (29)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Fluvoxamine | 2 |
| Lactulose, Vitamin D, Calcium | 1 |
| PROMETRIUM® 300 mg | 1 |
| PROMETRIUM® 400 mg | 1 |
| 17ß-Estradiol/Dydrogesterone | 1 |
Showing 5 of 29 approved assets.
Journals published in (100)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of clinical endocrinology and metabolism | 10 |
| The New England journal of medicine | 8 |
| The Journal of pharmacology and experimental therapeutics | 7 |
| Circulation | 5 |
| JAMA | 4 |
Showing 5 of 100 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 905 | 33 | 2025-10-07 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 2 | 2022-01-06 |
Organization relationships (16)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 2 |
| Iqvia Holdings Inc. | Uses vendor | 2 |
| Viatris | Co sponsors trial with | 1 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 1 |
| Children's Hospital of Philadelphia | Co sponsors trial with | 1 |
Showing 5 of 16 relationships.
Latest dated events (1,051)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-10-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-05-27 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-04-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-10-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-10-01 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 1,051 events.
Biomarker capability evidence (84)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| BTBD8 | Trial collaborator | Named in trial inclusion criteria |
| CELA1 | Trial collaborator | Named in trial inclusion criteria |
| DMRTA1 | Trial sponsor | Named in trial inclusion criteria |
| ERVK-10 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 84 evidence rows.
On Scientist.com
SOLVAY is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Solvay (Rhodia) on Scientist.com
For prices, more details, or to contact Solvay (Rhodia), visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.